Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment
Open Access
- 14 April 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-7
Abstract
The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization. We recently reported on the in vitro selection of SARS-CoV-2 3CLpro resistant virus (L50F-E166A-L167F; 3CLprores) that is cross-resistant with nirmatrelvir and other 3CLpro inhibitors. Here, we demonstrate that the 3CLprores virus replicates efficiently in the lungs of intranasally infected female Syrian hamsters and causes lung pathology comparable to that caused by the WT virus. Moreover, hamsters infected with 3CLprores virus transmit the virus efficiently to co-housed non-infected contact hamsters. Importantly, at a dose of 200 mg/kg (BID) of nirmatrelvir, the compound was still able to reduce the lung infectious virus titers of 3CLprores-infected hamsters by 1.4 log10 with a modest improvement in the lung histopathology as compared to the vehicle control. Fortunately, resistance to Nirmatrelvir does not readily develop in clinical setting. Yet, as we demonstrate, in case drug-resistant viruses emerge, they may spread easily which may thus impact therapeutic options. Therefore, the use of 3CLpro inhibitors in combination with other drugs may be considered, especially in immunodeficient patients, to avoid the development of drug-resistant viruses.Keywords
This publication has 26 references indexed in Scilit:
- Drug combination therapy for emerging viral diseasesDrug Discovery Today, 2021
- STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamstersNature Communications, 2020
- Distribution and evolution of H1N1 influenza A viruses with adamantanes‐resistant mutations worldwide from 1918 to 2019Journal of Medical Virology, 2020
- Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activityProceedings of the National Academy of Sciences, 2020
- The SARS-CoV-2 main protease as drug targetBioorganic & Medicinal Chemistry Letters, 2020
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitorsNature, 2020
- An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule ChemotherapyJournal of Medicinal Chemistry, 2016
- Hepatitis B virus resistance to antiviral drugs: where are we going?Liver International, 2011
- The substrate specificity of SARS coronavirus 3C-like proteinaseBiochemical and Biophysical Research Communications, 2005
- Herpes simplex virus resistance to antiviral drugsJournal of Clinical Virology, 2003